Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 12/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201968 | 0.89 | NOS2 (0.53) | NOS2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5204903 | 0.87 | NOS2 (0.58) | NOS2CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5203119 | 0.85 | NOS2 (0.49) | NOS2NOS1TSHR | |
| SCHEMBL5204696 | 0.85 | CYP1A2 (0.46) | NOS2NOS1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5205379 | 0.81 | MEN1 (0.44) | NOS2TSHR | |
| SCHEMBL5202231 | 0.77 | NOS2 (0.52) | NOS2NOS1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6942452 | 0.73 | NOS2 (0.57) | NOS2NOS1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5202697 | 0.73 | NOS2 (0.58) | NOS2NOS1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7068561 | 0.71 | CYP2D6 (0.77) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3559628 | 0.70 | NOS2 (0.78) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | claimed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | claimed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | claimed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1795192-A2 | 1-Substituted imidazole derivatives as nos inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-7202263-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-10 | — | — | US | disclosed |
| EP-1501504-B1 | 1-SUBSTITUTED IMIDAZOLE DERIVATIVES AS NOS INHIBITORS | SCHERING AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-6982259-B2 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-01-03 | — | — | US | disclosed |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094725-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885CYP1A2 27/4885 |
| US-20040023950-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885CYP1A2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.